Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)
Authors:
Open Access
Abstract
No abstract availableKeywords
Funding Information
- Takeda Pharmaceutical Company
- National Institutes of Health
- AstraZeneca
- Life Sciences, University of California, Los Angeles
- Breast Cancer Research Foundation
This publication has 35 references indexed in Scilit:
- Recent progress of CDK4/6 inhibitors’ current practice in breast cancerCancer Gene Therapy, 2024
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Overall survival in patients with hormone receptor-positive, HER2-negative, advanced or metastatic breast cancer treated with a cyclin-dependent kinase 4/6 inhibitor plus fulvestrant: a US Food and Drug Administration pooled analysisThe Lancet Oncology, 2021
- Breast Cancer Molecular Subtype as a Predictor of Radiation Therapy Fractionation SensitivityInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2021
- Quantifying CDK inhibitor selectivity in live cellsNature Communications, 2020
- Multiomics Profiling Establishes the Polypharmacology of FDA-Approved CDK4/6 Inhibitors and the Potential for Differential Clinical ActivityCell Chemical Biology, 2019
- Endocrine-Therapy-Resistant ESR1 Variants Revealed by Genomic Characterization of Breast-Cancer-Derived XenograftsCell Reports, 2013
- Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trialThe Lancet Oncology, 2013
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Risk factors by molecular subtypes of breast cancer across a population-based study of women 56 years or youngerBreast Cancer Research and Treatment, 2011